327 related articles for article (PubMed ID: 22112317)
1. Preclinical studies on histone deacetylase inhibitors as therapeutic reagents for endometrial and ovarian cancers.
Singh BN; Zhou H; Li J; Tipton T; Wang B; Shao G; Gilbert EN; Li Q; Jiang SW
Future Oncol; 2011 Dec; 7(12):1415-28. PubMed ID: 22112317
[TBL] [Abstract][Full Text] [Related]
2. Targeting histone deacetylases in endometrial cancer: a paradigm-shifting therapeutic strategy?
Garmpis N; Damaskos C; Garmpi A; Spartalis E; Kalampokas E; Kalampokas T; Margonis GA; Schizas D; Andreatos N; Angelou A; Lavaris A; Athanasiou A; Apostolou KG; Spartalis M; Damaskou Z; Daskalopoulou A; Diamantis E; Tsivelekas K; Alavanos A; Valsami S; Moschos MM; Sampani A; Nonni A; Antoniou EA; Mantas D; Tsourouflis G; Markatos K; Kontzoglou K; Perrea D; Nikiteas N; Kostakis A; Dimitroulis D
Eur Rev Med Pharmacol Sci; 2018 Feb; 22(4):950-960. PubMed ID: 29509243
[TBL] [Abstract][Full Text] [Related]
3. Histone Deacetylase Inhibitors: A Promising Therapeutic Alternative for Endometrial Carcinoma.
Psilopatis I; Pergaris A; Giaginis C; Theocharis S
Dis Markers; 2021; 2021():7850688. PubMed ID: 34804263
[TBL] [Abstract][Full Text] [Related]
4. Histones and lung cancer: Are the histone deacetylases a promising therapeutic target?
Petta V; Gkiozos I; Strimpakos A; Syrigos K
Cancer Chemother Pharmacol; 2013 Nov; 72(5):935-52. PubMed ID: 24036844
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy.
Ramaiah MJ; Tangutur AD; Manyam RR
Life Sci; 2021 Jul; 277():119504. PubMed ID: 33872660
[TBL] [Abstract][Full Text] [Related]
6. HDAC as a therapeutic target for treatment of endometrial cancers.
Ren J; Zhang J; Cai H; Li Y; Zhang Y; Zhang X; Zhao D; Li Z; Ma H; Wang J; Gao YE; Xiao L; Liu R; Qian J; Liu Y; Wei H; Li J
Curr Pharm Des; 2014; 20(11):1847-56. PubMed ID: 23888962
[TBL] [Abstract][Full Text] [Related]
7. Using Histone Deacetylase Inhibitors to Analyze the Relevance of HDACs for Translation.
Hutt DM; Roth DM; Marchal C; Bouchecareilh M
Methods Mol Biol; 2017; 1510():77-91. PubMed ID: 27761814
[TBL] [Abstract][Full Text] [Related]
8. Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
Hanikoglu A; Hanikoglu F; Ozben T
Curr Protein Pept Sci; 2018; 19(3):333-340. PubMed ID: 28059044
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells.
Dowdy SC; Jiang S; Zhou XC; Hou X; Jin F; Podratz KC; Jiang SW
Mol Cancer Ther; 2006 Nov; 5(11):2767-76. PubMed ID: 17121923
[TBL] [Abstract][Full Text] [Related]
10. M344 is a novel synthesized histone deacetylase inhibitor that induces growth inhibition, cell cycle arrest, and apoptosis in human endometrial cancer and ovarian cancer cells.
Takai N; Ueda T; Nishida M; Nasu K; Narahara H
Gynecol Oncol; 2006 Apr; 101(1):108-13. PubMed ID: 16263156
[TBL] [Abstract][Full Text] [Related]
11. Developing histone deacetylase inhibitors in the therapeutic armamentarium of pancreatic adenocarcinoma.
Zafar SF; Nagaraju GP; El-Rayes B
Expert Opin Ther Targets; 2012 Jul; 16(7):707-18. PubMed ID: 22621256
[TBL] [Abstract][Full Text] [Related]
12. A mechanistic approach to anticancer therapy: targeting the cell cycle with histone deacetylase inhibitors.
Mork CN; Faller DV; Spanjaard RA
Curr Pharm Des; 2005; 11(9):1091-104. PubMed ID: 15853658
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions.
Marks PA
Biochim Biophys Acta; 2010; 1799(10-12):717-25. PubMed ID: 20594930
[TBL] [Abstract][Full Text] [Related]
14. Cytostatic and apoptotic effects of DNMT and HDAC inhibitors in endometrial cancer cells.
Xu S; Ren J; Chen HB; Wang Y; Liu Q; Zhang R; Jiang SW; Li J
Curr Pharm Des; 2014; 20(11):1881-7. PubMed ID: 23888960
[TBL] [Abstract][Full Text] [Related]
15. HDAC inhibitors for the treatment of cancer.
Secrist JP; Zhou X; Richon VM
Curr Opin Investig Drugs; 2003 Dec; 4(12):1422-7. PubMed ID: 14763127
[TBL] [Abstract][Full Text] [Related]
16. Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines.
Bandolik JJ; Hamacher A; Schrenk C; Weishaupt R; Kassack MU
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234549
[TBL] [Abstract][Full Text] [Related]
17. Histone Deacetylases (HDACs): Evolution, Specificity, Role in Transcriptional Complexes, and Pharmacological Actionability.
Milazzo G; Mercatelli D; Di Muzio G; Triboli L; De Rosa P; Perini G; Giorgi FM
Genes (Basel); 2020 May; 11(5):. PubMed ID: 32429325
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents.
Mottamal M; Zheng S; Huang TL; Wang G
Molecules; 2015 Mar; 20(3):3898-941. PubMed ID: 25738536
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
20. Human endometrial and ovarian cancer cells: histone deacetylase inhibitors exhibit antiproliferative activity, potently induce cell cycle arrest, and stimulate apoptosis.
Takai N; Narahara H
Curr Med Chem; 2007; 14(24):2548-53. PubMed ID: 17979707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
